bevacizumab,olaparib
Roche,Merck,Astrazeneca
['lynparza', 'ovarian', 'brca', 'biomarker']
lynparza presents possibility of cure for some patients with biomarker-defined ovarian cancer. data from two phase iii studies showed at esmo that patients with brca1/2 mutations and hrd are living longer with maintenance therapy with lynparza alone... 